|
Analyst Support for Salix’s Relistor sNDA Sags as FDA Demands New Trial
Citing cardiovascular safety concerns, the FDA says Salix Pharmaceuticals must conduct a large, well-controlled, chronic administration trial if its sNDA for opioid-induced constipation (OIC) drug Relistor is to advance.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives